Avalo Therapeutics, Inc. (NASDAQ:AVTX) Shares Bought by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC grew its holdings in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 1,123.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 550,765 shares of the company’s stock after purchasing an additional 505,765 shares during the quarter. Affinity Asset Advisors LLC owned approximately 5.30% of Avalo Therapeutics worth $4,092,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of AVTX. Geode Capital Management LLC lifted its position in shares of Avalo Therapeutics by 937.0% in the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock valued at $779,000 after acquiring an additional 94,742 shares in the last quarter. Bank of Montreal Can acquired a new position in Avalo Therapeutics in the 4th quarter valued at about $446,000. Finally, Walleye Capital LLC purchased a new position in Avalo Therapeutics in the 4th quarter valued at about $145,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Stock Performance

AVTX stock opened at $5.38 on Tuesday. Avalo Therapeutics, Inc. has a 52 week low of $4.44 and a 52 week high of $18.79. The business has a fifty day simple moving average of $7.17 and a 200-day simple moving average of $8.83.

Analyst Ratings Changes

AVTX has been the subject of a number of recent research reports. Piper Sandler started coverage on shares of Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 price target for the company. BTIG Research initiated coverage on shares of Avalo Therapeutics in a research note on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $18.00 price target on shares of Avalo Therapeutics in a report on Thursday, March 20th. HC Wainwright restated a “neutral” rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Finally, Jefferies Financial Group initiated coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a “buy” rating and a $23.00 target price for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.00.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.